New drug shows promise for rare blistering skin condition

NCT ID NCT02226146

Completed Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This early study tested a drug called bertilimumab in 11 adults aged 60 and older with newly diagnosed bullous pemphigoid, a disease that causes painful blisters. The main goals were to check safety and see if the drug could reduce blistering. While results may guide future treatments, this is not a cure and ongoing management is likely needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGOID, BULLOUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Iowa City, Iowa, United States
Research Site

Buffalo, New York, United States
Research Site

New York, New York, United States
Research Site

Durham, North Carolina, United States
Research Site

Cleveland, Ohio, 10900, United States
Research Site

Salt Lake City, Utah, United States
Research Site

Ramat Gan, 5262100, Israel
Research Site

Tel Aviv, 64239, Israel

Conditions

Explore the condition pages connected to this study.

PEMPHIGOID, BULLOUS